Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00459862 · OUTCOME

Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST.

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma · Source last updated 2015-02-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
From study enrollment to the first date of disease progression

What was measured

Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline LD.

Analysis population: All 34 participants were evaluable for this endpoint.

Groups in this outcome

Arm I

Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I34

Reported measurements

Partial Response (PR)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm I5Not reportedNot reportedNot reportedNot reported
Complete Response (CR)
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm I0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        5
    title
    Partial Response (PR)
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Complete Response (CR)
denoms
  1. counts
    1. group Id
      OG000
      value
      34
    units
    Participants
description
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline LD.
groups
  1. description
    Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Arm I
param Type
NUMBER
population Description
All 34 participants were evaluable for this endpoint.
reporting Status
POSTED
time Frame
From study enrollment to the first date of disease progression
title
Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST.
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice